Malaria Information and Prophylaxis, by Country [S]
Country | Areas with Malaria | Drug Resistance2 | Malaria Species3 | Recommended Chemoprophylaxis4 | Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries |
---|---|---|---|---|---|
Saint Helena (U.K.) | None | Not Applicable | Not Applicable | Not Applicable | |
Saint Kitts (Saint Christopher) and Nevis (U.K.) | None | Not Applicable | Not Applicable | Not Applicable | |
Saint Lucia | None | Not Applicable | Not Applicable | Not Applicable | |
Saint Pierre and Miquelon (France) | None | Not Applicable | Not Applicable | Not Applicable | |
Saint Vincent and the Grenadines | None | Not Applicable | Not Applicable | Not Applicable | |
Samoa (formerly Western Samoa) | None | Not Applicable | Not Applicable | Not Applicable | |
San Marino | None | Not Applicable | Not Applicable | Not Applicable | |
São Tomé and Príncipe | All | Chloroquine | P. falciparum 85%,
P. malariae, P. ovale, and P. vivax 15% combined |
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6 | |
Saudi Arabia | Asir and Jazan emirates by border with Yemen. None in the cities of Jeddah, Mecca, Medina, Riyadh, and Ta’if. | Chloroquine | P. falciparum predominantly | Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6 | 1) City(ies) of travel 2) Emirate(s) of travel To determine if a city is within a certain emirateExternal Map of regions of Saudi ArabiaExternal |
Senegal | All | Chloroquine | P. falciparum >85%,
P. ovale 5-10%, P. vivax rare |
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6 | |
Serbia | None | Not Applicable | Not Applicable | Not Applicable | |
Seychelles | None | Not Applicable | Not Applicable | Not Applicable | |
Sierra Leone | All | Chloroquine | P. falciparum >85%,
P. ovale 5%-10%, P. malariae and P. vivax rare |
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6 | |
Singapore | None | Not Applicable | Not Applicable | Not Applicable | |
Slovakia | None | Not Applicable | Not Applicable | Not Applicable | |
Slovenia | None | Not Applicable | Not Applicable | Not Applicable | |
Solomon Islands | All | Chloroquine | P. falciparum 60%,
P. vivax 35-40%, P. ovale <1% |
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6 | |
Somalia | All | Chloroquine | P. falciparum 90%,
P. vivax 5%-10%, P. malariae, and P. ovale rare |
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6 | |
South Africa | Present along the border with Zimbabwe and Mozambique. Specifically in Mopani, Vhembe, and Waterberg district municipalities of Limpopo Province; Ehlanzeni district municipality in Mpumalanga Province; and Umknanyakude in Kwazulu-Natal Province. Present in Kruger National Park. | Chloroquine | P. falciparum 90%,
P. vivax 5%, P. ovale 5% |
Areas in Limpopo, Mpumalanga, and Kwazulu-Natal Provinces with malaria: Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6 |
Province(s) of travel
Provinces of South Africa to determine if a city is within a certain provinceExternal |
South Georgia and the South Sandwich Islands | None | Not Applicable | Not Applicable | Not Applicable | |
South Korea | Limited to the months of March–December in rural areas in the northern parts of Incheon, Kangwon-do, Kyônggi-do Provinces including the demilitarized zone (DMZ). | None | P. vivax 100% | Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, primaquine,6 or tafenoquine6
|
Provinces(s) of travel Administrative divisions of South KoreaExternal |
South Sudan, Republic of | All | Chloroquine | P. falciparum 90%,
P.vivax 5%–10%, P. malariae and P. ovale rare. |
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6 | |
Spain | None | Not Applicable | Not Applicable | Not Applicable | |
Sri Lanka | None | Not applicable | Not applicable | Not applicable | |
Sudan | All | Chloroquine | P. falciparum 90%,
P.vivax 5%–10%, P. malariae and P. ovale rare. |
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine | |
Suriname | Present in the municipality of Tapanahony in Sipaliwini Province. Rare cases in Brokopondo Province, Marowijne Province, and Boven Saramacca municipality in Sipaliwini Province. No malaria in Paramaribo. | Chloroquine | P. falciparum 70%,
P. vivax 15-20% |
Tapanahony municipality in Sipaliwini Province: Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6. Other areas with malaria: Mosquito avoidance only. |
Province(s) of travel
Map provinces of Suriname to determine if a city is within a certain provinceExternal |
Swaziland | Present in eastern areas bordering Mozambique and South Africa, including all of Lubombo district and the eastern half of Hhohho, Manzini, and Shiselweni districts. | Chloroquine | P. falciparum 90%,
P. ovale 5%, |
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6 | District(s) of travel
Districts of Swaziland to determine if a city is within a certain districtExternal |
Sweden | None | Not Applicable | Not Applicable | Not Applicable | |
Switzerland | None | Not Applicable | Not Applicable | Not Applicable | |
Syria | None | Not Applicable | Not Applicable | Not Applicable |
1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2. Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. This risk estimate is based largely on cases occurring in US military personnel who travel for extended periods of time with unique itineraries that likely do not reflect the risk for the average US traveler.
6. Primaquine and tafenoquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients must be screened for G6PD deficiency prior to starting primaquine.